| scholarly article | Q13442814 |
| P819 | ADS bibcode | 1996PNAS...93.4851R |
| P356 | DOI | 10.1073/PNAS.93.10.4851 |
| P932 | PMC publication ID | 39368 |
| P698 | PubMed publication ID | 8643492 |
| P5875 | ResearchGate publication ID | 14556056 |
| P50 | author | Eric A Pierce | Q37385160 |
| P2093 | author name string | L E Smith | |
| R Webb | |||
| E Foley | |||
| S L Rook | |||
| G S Robinson | |||
| P2860 | cites work | Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 | Q25938983 |
| Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo | Q29614729 | ||
| Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis | Q29617644 | ||
| Angiogenic factors | Q29620582 | ||
| Oligodeoxynucleoside phosphoramidates and phosphorothioates as inhibitors of human immunodeficiency virus | Q33650315 | ||
| Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders | Q34292807 | ||
| Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy | Q34324536 | ||
| Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization | Q34749337 | ||
| Antisense inhibition of oncogene expression | Q35226144 | ||
| Antisense oligonucleotides as antiviral agents | Q35301174 | ||
| Regulators of Angiogenesis | Q36653534 | ||
| Modulation of eukaryotic gene expression by complementary RNA or DNA sequences | Q38212410 | ||
| Vasculotropin-VEGF stimulates retinal capillary endothelial cells through an autocrine pathway. | Q38305663 | ||
| Antisense oligodeoxynucleotides to GS protein alpha-subunit sequence accelerate differentiation of fibroblasts to adipocytes | Q38327366 | ||
| Recent advances in diabetic retinopathy | Q40302190 | ||
| Endothelial receptor tyrosine kinases involved in angiogenesis. | Q40400431 | ||
| Antisense oligonucleotides as therapeutic agents--is the bullet really magical? | Q40834751 | ||
| Effect of oxygen on developing retinal vessels with particular reference to the problem of retrolental fibroplasia | Q40935597 | ||
| Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant | Q41488146 | ||
| Vascular endothelial growth factor. Regulation by cell differentiation and activated second messenger pathways | Q41608154 | ||
| Pathogenesis of ascites tumor growth: angiogenesis, vascular remodeling, and stroma formation in the peritoneal lining. | Q41664061 | ||
| Antisense oligonucleotides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms | Q41664990 | ||
| Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia | Q41677354 | ||
| Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. | Q44393459 | ||
| Implication of RNA structure on antisense oligonucleotide hybridization kinetics | Q45059437 | ||
| Gene inhibition using antisense oligodeoxynucleotides | Q46429559 | ||
| Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation. | Q50764794 | ||
| Concerning antisense inhibition of the multiple drug resistance gene. | Q54335272 | ||
| A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines | Q69614850 | ||
| Synthesis and secretion of vascular permeability factor/vascular endothelial growth factor by human retinal pigment epithelial cells | Q70764129 | ||
| Oxygen tension regulates the expression of angiogenesis factor by macrophages | Q71015308 | ||
| Oxygen-induced retinopathy in the mouse | Q71608431 | ||
| In vivo stability, disposition and metabolism of a “hybrid” oligonucleotide phosphorothioate in rats | Q71987560 | ||
| A rapid method for quantitation of oligodeoxynucleotide phosphorothioates in biological fluids and tissues | Q72747306 | ||
| Childhood diabetes. Its course, and influence on the second and third generations | Q79106106 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | neovascularization | Q1281049 |
| murine model | Q122890741 | ||
| P1104 | number of pages | 6 | |
| P304 | page(s) | 4851-4856 | |
| P577 | publication date | 1996-05-01 | |
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy | |
| P478 | volume | 93 |
| Q37011389 | 5-Lipoxygenase metabolite 4-HDHA is a mediator of the antiangiogenic effect of ω-3 polyunsaturated fatty acids |
| Q38022991 | A brief history of anti-VEGF for the treatment of ocular angiogenesis |
| Q33820526 | A clinical prediction model to stratify retinopathy of prematurity risk using postnatal weight gain |
| Q34208338 | A novel antiangiogenic peptide derived from hepatocyte growth factor inhibits neovascularization in vitro and in vivo |
| Q40662746 | A peptide encoded by exon 6 of VEGF (EG3306) inhibits VEGF-induced angiogenesis in vitro and ischaemic retinal neovascularisation in vivo. |
| Q37696351 | A review of clinical trials of anti-VEGF agents for diabetic retinopathy |
| Q46432751 | A single local injection of recombinant VEGF receptor 2 but not of Tie2 inhibits retinal neovascularization in the mouse |
| Q36618068 | Activated NAD(P)H oxidase from supplemental oxygen induces neovascularization independent of VEGF in retinopathy of prematurity model |
| Q38110394 | Algorithms for the prediction of retinopathy of prematurity based on postnatal weight gain |
| Q42456498 | An eye for discovery |
| Q24311459 | Angiogenesis promoted by vascular endothelial growth factor: regulation through alpha1beta1 and alpha2beta1 integrins |
| Q36424620 | Angiogenesis--a new target for future therapy |
| Q44654332 | Angiopoietin/Tek Interactions Regulate MMP-9 Expression and Retinal Neovascularization |
| Q24623508 | Annexin II regulates fibrin homeostasis and neoangiogenesis in vivo |
| Q53362175 | Anti-VEGF therapy for the treatment of glaucoma: a focus on ranibizumab and bevacizumab. |
| Q30666418 | Anti-angiogenic therapy of proliferative diabetic retinopathy |
| Q40960335 | Antisense oligonucleotides to the epidermal growth factor receptor |
| Q36003675 | Association of gene polymorphism with serum levels of inflammatory and angiogenic factors in Pakistani patients with age-related macular degeneration |
| Q35753400 | Basic fibroblast growth factor is neither necessary nor sufficient for the development of retinal neovascularization |
| Q35745444 | Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization |
| Q48580864 | Bowman Lecture 1998. Diabetic retinopathy: some cellular, molecular and therapeutic considerations |
| Q39661641 | Calpain inhibitors reduce retinal hypoxia in ischemic retinopathy by improving neovascular architecture and functional perfusion |
| Q44664918 | Captopril and vascular endothelial growth factor in a mouse model of retinopathy |
| Q30903366 | Cell injury unmasks a latent proangiogenic phenotype in mice with increased expression of FGF2 in the retina |
| Q43662174 | Circulating plasma vascular endothelial growth factor and microvascular complications of type 1 diabetes mellitus: the influence of ACE inhibition |
| Q33901062 | Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves the antiangiogenic efficacy for advanced stage mouse corneal neovascularization |
| Q38192060 | Current and investigational pharmacotherapeutic approaches for modulating retinal angiogenesis |
| Q37346456 | Decursin inhibits retinal neovascularization via suppression of VEGFR-2 activation |
| Q30631779 | Dramatic inhibition of retinal and choroidal neovascularization by oral administration of a kinase inhibitor |
| Q30724159 | Dynamics of phosphorothioate oligonucleotides in normal and laser photocoagulated retina |
| Q33868753 | Effect of brimonidine on retinal and choroidal neovascularization in a mouse model of retinopathy of prematurity and laser-treated rats |
| Q33185693 | Effective transfection of a cis element "decoy" of the nuclear factor-kappaB binding site into the experimental choroidal neovascularization |
| Q46891277 | Effects of the phosphatidylinositol 3-kinase inhibitor in a mouse model of retinal neovascularization |
| Q35566245 | Ethnic Variation in the Incidence and Severity of Retinopathy of Prematurity: Possible Explanations, Including Racial Differences in Illness Severity |
| Q34558870 | Experimental models of growth factor-mediated angiogenesis and blood-retinal barrier breakdown |
| Q35745334 | Expression of thrombospondin-1 in ischemia-induced retinal neovascularization |
| Q36397210 | Expression of vascular endothelial growth factor and its role in oncogenesis of human gastric carcinoma |
| Q28583644 | Expression of vascular endothelial growth factor and pigment epithelial-derived factor in a rat model of retinopathy of prematurity |
| Q35765120 | Expression of vascular endothelial growth factor in the human retina and in nonproliferative diabetic retinopathy. |
| Q28344709 | Gene transfer by viral vectors into blood vessels in a rat model of retinopathy of prematurity |
| Q28362039 | Glucose, VEGF-A, and diabetic complications |
| Q35648554 | Growth factors and protein kinase C inhibitors as novel therapies for the medical management diabetic retinopathy |
| Q40033199 | HIF-1α siRNA reduces retinal neovascularization in a mouse model of retinopathy of prematurity |
| Q43275526 | Hypothesis on the pathogenesis of retinopathy of prematurity--it is not VEGF alone but anatomical structures that are crucial |
| Q42155672 | Increased angiogenic factors associated with peripheral avascular retina and intravitreous neovascularization: a model of retinopathy of prematurity |
| Q35747297 | Inducible expression of vascular endothelial growth factor in adult mice causes severe proliferative retinopathy and retinal detachment |
| Q48086096 | Inhibition of VEGF mRNA by 2'-O,4'-C-ethylene-bridged nucleic acids (ENA) antisense oligonucleotides and their influence on off-target gene expressions |
| Q35088365 | Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization |
| Q42794620 | Inhibition of proliferative retinopathy by the anti-vascular agent combretastatin-A4. |
| Q44763476 | Inhibition of retinal neovascularisation by gene transfer of soluble VEGF receptor sFlt-1. |
| Q40753765 | Inhibitory effects of EGFR antisense oligodeox ynucleotide in human colorectal cancer cell line. |
| Q40692956 | Inhibitory mechanism of vascular endothelial growth factor (VEGF) by bucillamine |
| Q35813635 | Insulin like growth factor-1 and insulin-like growth factor binding proteins: their possible roles in both maintaining normal retinal vascular function and in promoting retinal pathology |
| Q43637135 | Intravitreal VEGF and bFGF produce florid retinal neovascularization and hemorrhage in the rabbit |
| Q45224240 | Intravitreal injection of specific receptor tyrosine kinase inhibitor PTK787/ZK222 584 improves ischemia-induced retinopathy in mice |
| Q42453872 | Intravitreal triamcinolone does not alter basal vascular endothelial growth factor mRNA expression in rat retina |
| Q40642055 | Intravitreous anti-raf-1 kinase antisense oligonucleotide as an angioinhibitory agent in porcine preretinal neovascularization |
| Q33219678 | Long-term evaluation of AAV-mediated sFlt-1 gene therapy for ocular neovascularization in mice and monkeys |
| Q35897076 | Low IGF-I suppresses VEGF-survival signaling in retinal endothelial cells: direct correlation with clinical retinopathy of prematurity. |
| Q37578873 | Mast cell chymase and tryptase as targets for cardiovascular and metabolic diseases |
| Q38069895 | Mechanisms and management of retinopathy of prematurity |
| Q42717540 | Moderate GSK-3β inhibition improves neovascular architecture, reduces vascular leakage, and reduces retinal hypoxia in a model of ischemic retinopathy |
| Q34238103 | Moderation of calpain activity promotes neovascular integration and lumen formation during VEGF-induced pathological angiogenesis |
| Q42803718 | Molecular framework for angiogenesis: a complex web of interactions between extravasated plasma proteins and endothelial cell proteins induced by angiogenic cytokines |
| Q28362790 | More weapons in the arsenal against ischemic retinopathy |
| Q37942156 | Nano-vectors for the Ocular Delivery of Nucleic Acid-based Therapeutics. |
| Q38913007 | Neurovascular cross talk in diabetic retinopathy: Pathophysiological roles and therapeutic implications |
| Q41829449 | Neutralizing antibody to VEGF reduces intravitreous neovascularization and may not interfere with ongoing intraretinal vascularization in a rat model of retinopathy of prematurity. |
| Q37777001 | New Approaches to Blockade of the Renin–Angiotensin–Aldosterone System: Chymase as an Important Target to Prevent Organ Damage |
| Q39755127 | Norrin promotes vascular regrowth after oxygen-induced retinal vessel loss and suppresses retinopathy in mice. |
| Q34805398 | Novel protective properties of IGFBP-3 result in enhanced pericyte ensheathment, reduced microglial activation, increased microglial apoptosis, and neuronal protection after ischemic retinal injury. |
| Q52172692 | Oligonucleotide-based inhibition of embryonic gene expression. |
| Q35140846 | Ophthalmic drug discovery |
| Q45151519 | Overexpression of VEGF-A induces neovascularization and increased vascular leakage in rabbit eye after intravitreal adenoviral gene transfer |
| Q34805909 | PEI-g-PEG-RGD/small interference RNA polyplex-mediated silencing of vascular endothelial growth factor receptor and its potential as an anti-angiogenic tumor therapeutic strategy |
| Q51568377 | POSTNATAL SERUM INSULIN-LIKE GROWTH FACTOR I AND RETINOPATHY OF PREMATURITY. |
| Q34546104 | Pathogenesis of retinopathy of prematurity |
| Q41853291 | Pharmacologic and genetic manipulation of MMP-2 and -9 affects retinal neovascularization in rodent models of OIR. |
| Q33194915 | Pharmacologic therapy for diabetic retinopathy |
| Q33997311 | Pharmacological treatment for retinopathy of prematurity |
| Q31065469 | Potential long-term inhibition of ocular neovascularisation by recombinant adeno-associated virus-mediated secretion gene therapy |
| Q34626222 | Potential new medical therapies for diabetic retinopathy: protein kinase C inhibitors |
| Q32063152 | Preclinical evaluation of a phosphorothioate oligonucleotide in the retina of rhesus monkey |
| Q34477473 | Prevention of ischemia-induced retinopathy by the natural ocular antiangiogenic agent pigment epithelium-derived factor |
| Q35787073 | Pro-inflammatory cytokines induce expression of matrix-metabolizing enzymes in human cervical smooth muscle cells |
| Q35156007 | RNA interference-based therapy for spinocerebellar ataxia type 7 retinal degeneration. |
| Q37256549 | Recent perspectives in ocular drug delivery |
| Q45858295 | Reduction of fibronectin expression by intravitreal administration of antisense oligonucleotides. |
| Q73226153 | Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor |
| Q64937118 | Retinal Vasculature in Development and Diseases. |
| Q35566836 | Retinal and choroidal angiogenesis: pathophysiology and strategies for inhibition |
| Q41520625 | Retinal development: Communication helps you see the light |
| Q33606227 | Retinopathy of prematurity: current concepts in molecular pathogenesis |
| Q34475449 | Review of therapeutic advances in diabetic retinopathy |
| Q35300661 | Role of vascular permeability factor/vascular endothelial growth factor in eye disease |
| Q24531302 | Selective induction of neuropilin-1 by vascular endothelial growth factor (VEGF): a mechanism contributing to VEGF-induced angiogenesis |
| Q55472739 | Structure and inhibitory effects on angiogenesis and tumor development of a new vascular endothelial growth inhibitor. |
| Q33787955 | Studies on the pathogenesis of avascular retina and neovascularization into the vitreous in peripheral severe retinopathy of prematurity (an american ophthalmological society thesis) |
| Q38373964 | Study protocol: safety and efficacy of propranolol 0.2% eye drops in newborns with a precocious stage of retinopathy of prematurity (DROP-ROP-0.2%): a multicenter, open-label, single arm, phase II trial. |
| Q33379554 | Suppression of retinal neovascularization by erythropoietin siRNA in a mouse model of proliferative retinopathy |
| Q46318087 | Suppression of retinal neovascularization by shRNA targeting HIF-1alpha |
| Q46081402 | Suppression of retinal neovascularization by the iNOS inhibitor aminoguanidine in mice of oxygen-induced retinopathy |
| Q37835286 | Targets of chymase inhibitors |
| Q35643535 | Temporal and spatial changes in VEGF, αA- and αB-crystallin expression in a mouse model of oxygen-induced retinopathy |
| Q28504605 | The 67-kd laminin receptor is preferentially expressed by proliferating retinal vessels in a murine model of ischemic retinopathy |
| Q38110390 | The biology of retinopathy of prematurity: how knowledge of pathogenesis guides treatment |
| Q37565247 | The effects of oxygen stresses on the development of features of severe retinopathy of prematurity: knowledge from the 50/10 OIR model |
| Q30495106 | The mouse retina as an angiogenesis model |
| Q34658478 | The pathogenesis of diabetic retinopathy: old concepts and new questions |
| Q38101684 | The pathophysiology of retinopathy of prematurity: an update of previous and recent knowledge |
| Q31123344 | The potential role of PKC beta in diabetic retinopathy and macular edema |
| Q31061150 | The role of angiogenesis in the development of proliferative diabetic retinopathy: impact of intravitreal anti-VEGF treatment |
| Q27021701 | Therapeutic interventions against inflammatory and angiogenic mediators in proliferative diabetic retinopathy |
| Q35028866 | Tranilast inhibits protein kinase C-dependent signalling pathway linked to angiogenic activities and gene expression of retinal microcapillary endothelial cells |
| Q38335452 | Transcription factors Sp1 and Sp3 alter vascular endothelial growth factor receptor expression through a novel recognition sequence |
| Q35763708 | Transgenic mice with increased expression of vascular endothelial growth factor in the retina: a new model of intraretinal and subretinal neovascularization |
| Q45264621 | Upregulation of placental growth factor by vascular endothelial growth factor via a post-transcriptional mechanism. |
| Q34451927 | VEGF antagonists |
| Q35950867 | Vascular Endothelial Growth Factor and Diabetic Retinal Disease |
| Q34280300 | Vascular endothelial growth factor and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives. |
| Q35763668 | Vascular endothelial growth factor and ocular neovascularization. |
| Q48605197 | Vascular endothelial growth factor and severity of nonproliferative diabetic retinopathy mediate retinal hemodynamics in vivo: a potential role for vascular endothelial growth factor in the progression of nonproliferative diabetic retinopathy |
| Q36502592 | Vascular endothelial growth factor antisense oligodeoxynucleotides with lipiodol in arterial embolization of liver cancer in rats. |
| Q38153731 | Vascular endothelial growth factor gene polymorphisms and vitreous proteome changes in diabetic retinopathy |
| Q46219956 | [Pathogenesis of retinopathy of prematurity]. |
Search more.